hit counter
Cerus Corporation (CERS) Stock News Sentiment & Price - Sentifly
CERS - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Cerus Corporation (CERS)

USA
Biotechnology
NASDAQ
CERS Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
CERS Latest news
Business Wire
Neutral
Cerus Corporation to Participate in Stifel 2021 Virtual Healthcare Conference
2021-11-08 08:00

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that William ‘Obi' Greenman, Cerus' president and chief executive officer, and Kevin D. Green, Cerus' chief financial officer, are scheduled to participate in the Stifel 2021 Virtual Healthcare Conference on Monday, November 15, 2021 at 4:40 p.m. ET. A live webcast of the events will be available on the Investor Relations page of the Cerus web site at http://www.cerus.com/ir. A replay will be available for approx

Seeking Alpha
Neutral
Cerus Corporation (CERS) CEO Obi Greenman on Q3 2021 Results - Earnings Call Transcript
2021-11-02 22:09

Cerus Corporation (CERS) CEO Obi Greenman on Q3 2021 Results - Earnings Call Transcript

Zacks Investment Research
Positive
Cerus (CERS) Reports Q3 Loss, Tops Revenue Estimates
2021-11-02 19:09

Cerus (CERS) delivered earnings and revenue surprises of 30.00% and 14.34%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Business Wire
Neutral
Cerus Corporation Announces Record Third Quarter 2021 Financial Results and Raises Full-Year Product Revenue Guidance
2021-11-02 16:00

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2021. Recent developments and highlights include: Third quarter 2021 total revenue of $42.1 million, reflecting a 44% increase over the prior year period. Total revenue was composed of (in thousands, except %):   Three Months Ended         Nine Months Ended         September 30,         September 30,         2021   2020   Change     2021   2020   Change

Zacks Investment Research
Negative
Analysts Estimate Cerus (CERS) to Report a Decline in Earnings: What to Look Out for
2021-10-26 16:40

Cerus (CERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire
Neutral
Cerus Corporation to Release Third Quarter 2021 Financial Results on November 2, 2021
2021-10-19 08:00

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2021 financial results will be released on Tuesday, November 2, 2021, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the

GuruFocus
Neutral
Undervalued Stocks That Catherine Wood and Ron Baron Agree On
2021-10-12 15:06

According to the GuruFocus Scoreboard, where users can sort investing gurus based on their fund performances over specific periods of time, the gurus that posted the highest gains during the most recent year were Catherine Wood (Trades, Portfolio) and Ron Baron (Trades, Portfolio). For full-year 2020, Wood's Ark Investment Management returned 152.50%, while Ron Baron (Trades, Portfolio)'s Baron Funds gained 148.50%.

Business Wire
Neutral
Cerus Corporation Applauds FDA Requirements Effective Today to Safeguard the U.S. Platelet Supply
2021-10-01 08:00

CONCORD, Calif.--(BUSINESS WIRE)--Today marks the effective date for the U.S. Food and Drug Administration's (FDA) final guidance document on bacterial risk control strategies for platelet collection and transfusion. This guidance for industry, “Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelet for Transfusion,” which was finalized in 2020, identifies FDA-approved pathogen reduction as a means of com

Business Wire
Neutral
Cerus Corporation Announces INTERCEPT Fibrinogen Complex Customer Presentations at SABM Virtual Annual Meeting 2021
2021-09-20 08:00

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced its participation in the Society for the Advancement of Blood Management (SABM) Virtual Annual Meeting, which is scheduled for September 22-25, 2021. On Thursday, September 23, Cerus will host an industry workshop, “Clinical need for and experience with the new Pathogen Reduced Cryoprecipitated Fibrinogen Complex (INTERCEPT Fibrinogen Complex),” from 1:00-1:30p.m. EDT featuring two hospital customers currently us

Seeking Alpha
Neutral
Cerus Corp.: Record Revenue Warrants A Slight Change In Strategy
2021-09-16 21:17

Cerus Corp.: Record Revenue Warrants A Slight Change In Strategy

Loading more news...